A study of once-daily tacrolimus for new lung transplant patients
Part of Lungs & breathing clinical trials.
This trial tests a special form of tacrolimus (Envarsus) taken once daily to prevent organ rejection in people who recently received a first lung transplant. The study will follow patients for at least 12 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You received your first single or double lung transplant.
- You started taking Envarsus (a once-daily form of tacrolimus) within 3 months after transplant.
- You and your doctor expect you to continue treatment for at least 12 months.
- You are able to give permission (informed consent) to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a long-acting form of tacrolimus (a common anti-rejection medicine) soon after lung transplant. It aims to see if it can be used safely and effectively for people receiving lung transplants at Vanderbilt (VUMC).
This trial studies whether taking an extended-release form of tacrolimus (a medicine to prevent transplant rejection) after a liver transplant works well for people who are followed at the University of Alberta. It may help simplify dosing and monitor safety and effectiveness after transplant.
This study tests whether taking immunosuppressive drugs (tacrolimus and mycophenolate mofetil) just once a day, instead of twice, works as well for people who recently had a liver transplant. The goal is to make the medication schedule easier and possibly safer.
This study looks at how well a once-daily anti-rejection medicine (Envarsus) works in people who have just had a kidney transplant. It helps doctors understand the best way to use this medicine and manage side effects.
This trial looks at whether changing your maintenance anti-rejection medicine from Prograf (usually twice daily) to Envarsus (once daily) can help keep your liver and kidney function stable. It targets people who may be having kidney side effects, symptoms from tacrolimus, or trouble taking a twice-daily medicine.
This study compares two long-acting forms of tacrolimus (Envarsus and Advagraf) to see how the body processes them after a kidney transplant. It aims to find the best way to use these medications to prevent organ rejection.
Hear when a new Lung Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.